Strategies for therapeutic interchange of biotechnology medicines: Proceedings of an invitational conference

Hospital Pharmacy

Volumn 35, Issue 4, 2000, Pages 377-386

  Bergstrom, Kimberly ^a,f   Ellis, Michael ^b   Keenan Milligan, Marilyn ^c   Mucenski, John W ^d   Williams, Donald H ^e  

^a Disease Management   (United States)

^b Olsten Health Services ^*  (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^e Washington State Board of Pharmacy   (United States)

^f OnCare   (United States)

Author keywords

Biotechnology products; Financial management; Formulary management; Quality of care; Therapeutic interchange

Indexed keywords

BECAPLERMIN; BLOOD CLOTTING FACTOR 8; COLONY STIMULATING FACTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GROWTH HORMONE; HUMAN GROWTH HORMONE; INSULIN; INTERFERON; MONOCLONAL ANTIBODY; OXANDROLONE; RECOMBINANT ERYTHROPOIETIN;

BIOTECHNOLOGY; CONFERENCE PAPER; COST CONTROL; DRUG COST; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE QUALITY; LAW; LEGAL ASPECT; PATIENT CARE; PUBLICATION; RISK MANAGEMENT;

EID: 0034081029     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870003500411     Document Type: Conference Paper

References (22)

1. O'Connell MB, Seay RE. Therapeutic interchange in Minnesota hospital pharmacies. Hosp Pharm. 1996;31:682-8.
2. Crawford SY, Santell JP. ASHP national survey of pharmaceutical services in federal hospitals - 1993. Am J Hosp Pharm. 1994;51:2377-93.
3. Reeder CE, Dickson M, Kozma CM, et al. ASHP national survey of pharmacy practice in acute care settings - 1996. Am J Health-Syst Pharm. 1997;54:653-69.
4. Doering PL, Russell WL, McCormick WC, et al. Therapeutic substitution in the health maintenance organization outpatient environment. Drug Intell Clin Pharm. 1988;22:125-30.
5. American Medical Association. AMA policy on drug formularies and therapeutic interchange in inpatient and ambulatory patient care settings. Am J Hosp Pharm. 1994;51:1808-10.
6. Academy of Managed Care Pharmacy. AMCP position statement on therapeutic interchange. September 13, 1997. www. amcp.org/public/legislative/position/therapeutic.html
7. ASHP guidelines on formulary system management. Am J Hosp Pharm. 1992; 49:648-52.
8. American College of Clinical Pharmacy. ACCP position statement: Guidelines for therapeutic interchange. Pharmacotherapy. 1993;13(3):252-6.
9. Health Care Financing Administration. Medicare definition of fraud. February 19, 1998. www.hcfa.gov/medicare/fraud/defini2.htm
10. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12:2471-508.
11. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol. 1996;14:1957-60.
12. American Society of Clinical Oncology. 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice 13. National Institutes of Health. Management of Hepatitis C: National Institutes of Health Consensus Development Conference Statement. March 24-26, 1997. www.text.nlm.nih.gov/nih/cdc/www/105. html.
13. Ramspacher S, Hough J. 1996 IMS hospital pharmacy review leading dollar volume pharmaceuticals. Hosp Pharm. 1997;32:774-99.
14. Home page: www.hcfa.gov
15. Medicare Statistics and Data: www.hcfa. gov/stats/stats. htm Public Use Files: www.hcfa.gov/stats/ pufiles. htm
16. Medicaid Information: www.hcfa.gov/ medicaid/medicaid.htm
17. Medicare Professional/Technical Information: www.hcfa.gov/medicare/mcarpti.htm
18. Medicare Payment Advisory Commission home page: www.pprc.gov/default_index. html
19. Catizone, CA, ed. Survey of pharmacy law 1997-1998. Park Ridge, IL: National Association of Boards of Pharmacy; 1997.
20. NABPLAW (ver 2.2a) Park Ridge, IL: National Association of Boards of Pharmacy; 1998.
21. Wall DS, Abel SR. Therapeutic-interchange algorithm for multiple drug classes. Am J Health-Syst Pharm. 1996;53:1295-6.
22. Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. www.fda.gov/cder/ob